Evidence map›Paper›PMID 39280062›Full record

ArticleChemical engineering journal (Lausanne, Switzerland : 1996)2023

Mitigating Metal-Organic Framework (MOF) Toxicity for Biomedical Applications.

Paulina Wiśniewska, Józef Haponiuk, Mohammad Reza Saeb, Navid Rabiee, Sidi A Bencherif

Abstract read
In one paragraph

Article in Chemical engineering journal (Lausanne, Switzerland : 1996), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. The MOF-Microbiome Axis: a New Paradigm for Precision Nanomedicine.Probiotics and antimicrobial proteins · 2026
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paulina WiśniewskaDepartment of Polymer Technology, Faculty of Chemistry, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233 Gdańsk, Poland.
Józef HaponiukDepartment of Polymer Technology, Faculty of Chemistry, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233 Gdańsk, Poland.
Mohammad Reza SaebDepartment of Polymer Technology, Faculty of Chemistry, Gdańsk University of Technology, Gabriela Narutowicza 11/12, 80-233 Gdańsk, Poland.
Navid RabieeCentre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Western Australia, 6150 Australia.
Sidi A BencherifChemical Engineering Department, Northeastern University, Boston, MA 02155, USA.

Funding

Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapyR01EB027705 · NIBIB · NORTHEASTERN UNIVERSITY · PI HATFIELD, STEPHEN MATTHEW · 2021 to 2024
$1.9M
NIBIB NIH HHS R01 EB027705
6 · The paper itself

Abstract

Metal-organic frameworks (MOFs) are a novel class of crystalline porous materials, consisting of metal ions and organic linkers. These hybrid materials possess exceptional porosity and specific surface area, which have recently garnered significant interest due to their potential applications in gas separation and storage, energy storage, biomedical imaging, and drug delivery. As MOFs are being explored for biomedical applications, it is essential to comprehensively assess their toxicity. Although nearly ninety thousand MOFs have been investigated, evaluating and optimizing their physico-chemical properties in relevant biological systems remain critical for their clinical translation. In this review article, we first provide a brief classification of MOFs based on their chemical structures. We then conduct a comprehensive evaluation of

Indexed as

biocompatibilitybiomedical applicationsframeworkmetal-organicnanoparticlestoxicity

Identifiers

PMID39280062
PMCPMC11394873

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.